Method for prognosis and / or diagnosis of a dandruff condition of the scalp
Measuring the active form of TGM3 in scalp samples allows for accurate diagnosis and treatment of dandruff, addressing the inefficiencies of current treatments and predicting dandruff recurrence.
Patent Information
- Application Number
- FR2020013349
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-16
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2040-12-16
AI Technical Summary
Current treatments for dandruff are suspensive and often lead to rebound phenomena, and there is a lack of understanding regarding the intimate mechanisms involved in skin desquamation and dandruff formation, necessitating new biomarkers for characterization and prediction of dandruff conditions.
Measuring the quantity of the active form of transglutaminase 3 (TGM3) in a scalp sample to diagnose and treat dandruff conditions, using a method that includes measuring TGM3 levels with specific antibodies and implementing cosmetic treatments based on the results.
Provides a reliable method for diagnosing and treating dandruff by identifying and reducing TGM3 levels, thereby effectively managing and preventing dandruff recurrence.
Smart Images

Figure 00000015_0000 
Figure 00000016_0000
Abstract
Description
Title of the invention: Method for prognosis and / or diagnosis of a dandruff condition of the scalp
[0001] The present invention relates to a method for prognosis and / or diagnosis of a dandruff condition of the scalp, based on the measurement of the quantity of the active form of transglutaminase 3. The present invention also relates to a method for cosmetic treatment of the scalp, a method for identifying compounds allowing the reduction and / or elimination of the dandruff condition. Finally, the present invention relates to a kit and its use for the identification of a compound allowing the reduction and / or elimination of the dandruff condition.
[0002] The skin, and in particular the scalp, is a continually renewing epithelium. Renewal, or desquamation, is a coordinated and finely regulated process resulting in the elimination of superficial cells, in a non-sensible and non-visible manner. However, abnormal or irregular desquamation of the cells of the stratum corneum, for various reasons, can lead to the formation of large, thick clumps of cells, visible to the naked eye, and called "scales" or "dandruff" in the context of the scalp, or in other situations, to a thinning of the stratum corneum.
[0003] As examples of factors promoting the appearance of scales or dandruff, we can mention stress, the winter period, excess sebum, a lack of hydration, and / or colonization of the skin or hair follicles by the yeast Malassezia sp. In particular, yeasts of the type Malassezia sp., constituting a part of the normal commensal flora on the surface of the scalp in subjects without dandruff, see their proportion increase substantially in the case of dandruff.
[0004] The presence of scales or dandruff conditions can be chronic, frequent, recurring, and socially disabling conditions due to their obvious unsightly nature. What is more, dandruff conditions of the scalp or abnormal desquamation of the skin can result in itching sensations, leading to scratching behaviors amplifying the phenomenon of the appearance of scales or dandruff.
[0005] Dandruff conditions of the scalp can be oily or dry. Dry dandruff conditions of the scalp occur more frequently. Since the scalp is rich in sebaceous glands, a dandruff condition can develop more easily in the presence of excessive sebum. Thus, excessive sebum secretion, or hyperseborrhea, promotes the appearance of a greasy dandruff condition of the scalp, or oily dandruff, generally associated with unpleasant sensations and discomfort. and aesthetic disorders. Dandruff conditions generally respond to various local or systemic treatments. However, the effectiveness of these treatments is only suspensive and often requires rigorous monitoring by the user (frequency of use and sufficient application time). However, daily and long-term use of these treatments can lead to a phenomenon of habituation reducing their effectiveness, and generally associated with a rebound phenomenon occurring when treatment is stopped. This phenomenon manifests itself as hyperseborrhea, aggravating the dandruff condition. Furthermore, the aggressiveness of certain anti-dandruff active ingredients towards epidermal cells or the ecoflora of the scalp can also cause a worsening of the dandruff condition.
[0006] Many epidermal factors, whose expression, biological activity or maturation are altered, decreased or increased, are known to be involved, directly or indirectly, in the process of renewal, or desquamation of the skin, and in particular of the scalp. However, there are still many unknowns regarding the intimate mechanism and the factors involved in the desquamation of the skin, and in particular in the appearance of dandruff.
[0007] There is therefore a need to have new biomarkers allowing the characterization of a dandruff condition of the scalp or the prediction of the appearance of a dandruff condition, in particular allowing relapses to be anticipated.
[0008] The present invention aims to meet this need.
[0009] The present invention results from the inventors' unexpected discovery that the amount of the active form of transglutaminase 3 (TGM3) was linked to the dandruff condition in a scalp. They indeed showed a significant increase in the amount of the active form of TGM3 in samples of dandruff scalp compared to normal scalp.
[0010] TGM3 catalyzes the formation of isopeptide crosslinks between glutamine and lysine residues in various proteins, as well as the conjugation of polyamines to proteins. In hair follicles, it is involved in the crosslinking of structural proteins to harden the inner root sheath.
[0011] TGM3 is encoded by a 42.8 kb gene containing 13 exons. It is located on chromosome 20: 2,296,001-2,341,079, on the sense strand. TGM3 is produced in the form of a proform having the amino acid sequence SEQ ID NO: 3, of 693 amino acids (and having the nucleotide sequence SEQ ID NO: 4). This enzyme is activated by proteolytic treatment of the proform, generating the active form. The active form thus produced has the amino acid sequence SEQ ID NO: 1 of 470 amino acids (and the nucleotide sequence SEQ ID NO: 2).
[0012] Expression of the proform of TGM3 was identified by mass spectrometry as being decreased in dandruff scalps compared to normal scalps. (Cavusoglu et al., Archives of Dermatological Research volume 308, pages 631-642 (2016). However, the inventors here discovered that the amount of the active form, detectable by a simple Elisa test, was increased and not decreased in dandruff-prone scalps. However, there is no direct correlation between the amount of the proform and the amount of the active form of a protein, these two quantities being dependent on various factors (such as the rate of production of the proform, the rate of conversion of the proform into the active form, the rate of degradation of the proform and the rate of degradation of the active form).
[0013] The present invention thus relates to a method for prognosis and / or diagnosis of a dandruff condition of the scalp, in a subject, said method comprising the following step:
[0014] a. measuring the amount of the active form of transglutaminase 3 (TGM3), in a scalp sample of said subject.
[0015] The present invention also relates to a method for the prevention and / or cosmetic treatment of the scalp presenting a dandruff condition in a subject, said method comprising the following steps:
[0016] a. measuring the quantity of the active form of TGM3, in a sample of scalp of said subject; b. deducing from step a) whether the scalp of said subject has a dandruff condition or whether the scalp of said subject is likely to develop a dandruff condition; c. if the scalp is identified as having a dandruff condition or as being likely to develop a dandruff condition in step b), treating said scalp with a cosmetic composition against the dandruff condition.
[0017] The present invention also relates to a method for identifying a compound allowing the prevention and / or reduction and / or elimination of the dandruff condition of a scalp, said method comprising the following steps:
[0018] a. measuring the amount of the active form of TGM3, in a sample of scalp exposed to said candidate compound; b. comparing said quantity measured in step a) to the quantity of the active form of TGM3 in a sample of scalp not exposed to said compound; c. identifying said candidate compound as a compound for preventing and / or reducing and / or eliminating the dandruff condition of a scalp when a decrease in the amount of the active form of TGM3 in the scalp sample that has been exposed to said candidate compound is detected, compared to the amount of the active form of TGM3 in the scalp sample that has not been exposed to the candidate compound.
[0019] The present invention also relates to a kit comprising:
[0020] a. a means for measuring in a scalp sample, the quantity of the active form of TGM3, and b. an instruction leaflet.
[0021] The present invention also relates to the use of a kit according to the invention for the identification of a compound allowing the prevention and / or reduction and / or elimination of the dandruff condition of a scalp. Detailed description of the invention
[0022] The active form of TGM3
[0023] By "the active form of active TGM3" is meant here the TGM3 protein after proteolytic cleavage. Preferably the active form of TGM3 has at least 80%, at least 90n or at least 95% identity with the sequence SEQ ID NO: 1. Preferably the active form of TGM3 has the amino acid sequence SEQ ID NO: 1. It is detectable in particular by antibodies specific for the active form.
[0024] By "antibody specific for the active form of TGM3" is meant an antibody which binds to the active form of TGM3 and which, in particular, does not bind to the proform of TGM3.
[0025] Method of prognosis and / or diagnosis
[0026] The present invention thus relates to a method for prognosis and / or diagnosis of a dandruff condition of the scalp.
[0027] By "dandruff condition of the scalp" is meant a scalp with excessive dryness or excessive sebum secretion, characterized by the presence of dry or oily dandruff, and possibly pruritus. Dry dandruff conditions are sometimes associated with excessively rapid renewal of the stratum corneum. Dry dandruff is generally small, white or gray, and is distributed on the scalp and clothing, generating an unsightly visual effect and is sometimes accompanied by itching. Oily dandruff conditions are often characterized by large, oily, yellow scales that accumulate to form clumps. They are sometimes accompanied by itching and burning sensations in the affected areas. Oily dandruff conditions of the scalp occur and are amplified during excessive sebum secretion in the epidermis of the scalp.
[0028] The method for prognosis and / or diagnosis of a dandruff condition of the scalp, according to the invention, comprises a step a) of measuring the quantity of the active form of transglutaminase 3 (TGM3), in a sample of scalp of said subject.
[0029] The amount of the active form of transglutaminase 3 (TGM3) can be measured by any suitable technique. In particular, the amount can be measured by mass spectrometry or by ELISA test. Preferably it is measured using a ligand specific for the active form of TGM3. In a preferred embodiment of the invention, the amount of the active form of transglutaminase 3 (TGM3) is measured by ELISA test.
[0030] The scalp sample of the subject used in the prognostic and / or diagnostic method according to the invention is a sample taken, preferably non-invasively, from the scalp of the subject, in particular from the temples of the subject. Preferably, the scalp sample comes from the stratum corneum, in particular from the surface of the stratum corneum.
[0031] The stratum corneum is the outermost layer of the epidermis, and comprises the surface of the skin. It is composed mainly of dead cells.
[0032] According to one embodiment, the prognostic and / or diagnostic method according to the invention comprises a step of taking the scalp sample from the subject, in particular from the surface of the scalp of the subject. This step is preferably carried out in a non-invasive manner, and in particular does not require local anesthesia. According to a preferred embodiment, the step of taking the sample is carried out by rubbing the scalp surface, or by using an adhesive surface, for example a D-squame® disc. In the case of the adhesive surface, this is applied to the scalp and then removed in order to take a sample from the surface of the scalp.
[0033] In a particular embodiment, the scalp sample is thus taken by rubbing the surface of said scalp, for example using a cotton swab or a sterile swab, or by using an adhesive surface, for example a D-squame® disc.
[0034] By “subject” is meant here a human being, preferably aged between 20 and 70 years.
[0035] In a particular embodiment, the prognostic and / or diagnostic method according to the invention further comprises the steps of:
[0036] (b) comparing the amount of the active form of TGM3 measured in step (a) with a control, and
[0037] (c) based on the comparison in step (b), determining whether the scalp of said subject is a dandruff scalp or a scalp susceptible to developing a dandruff condition.
[0038] By "likely to develop a dandruff condition of the scalp" is meant a scalp having presented at least once previously a dandruff condition of the scalp and / or a scalp not yet presenting dry or oily dandruff but presenting early signs of the appearance of dandruff such as itching.
[0039] In a particular embodiment, the scalp of said subject is diagnosed as being dandruff-prone or as being susceptible to developing a dandruff-prone condition. when the amount of the active form of TGM3 measured in step (a) in the subject's scalp sample is higher, in particular significantly higher, than a control.
[0040] In a particular embodiment, the control is a reference value.
[0041] In a particular embodiment, the reference value is determined by the average value of the quantity of the active form of TGM3 measured in a given population, for example a population in a given age group, and / or having a defined scalp type.
[0042] In a particular embodiment, the reference value is between 9 ng / ml and 12 ng / ml of TGM3, such as 10.44 ng / ml of TGM3.
[0043] In a particular embodiment, the control is the average value of the quantity of the active form of TGM3 measured in a population of subjects, in particular subjects as defined below, having a normal scalp.
[0044] By "normal scalp" is meant here a scalp which does not show the signs of a dandruff scalp such as the presence of dry or oily dandruff or pruritus.
[0045] In a particular embodiment, the reference value is determined by a ROC study.
[0046] By "significantly higher" and "significantly lower" for the purposes of the invention, we mean a statistically significant variation in the quantity of the active form of TGM3.
[0047] Cosmetic treatment method
[0048] The present invention relates to a method for the prevention and / or cosmetic treatment of the scalp presenting a dandruff condition in a subject, said method comprising the following steps:
[0049] a. Measuring the amount of the active form of TGM3 in a scalp sample from said subject; b. deducing from step a) whether the scalp of said subject has a dandruff condition or whether the scalp of said subject is likely to develop a dandruff condition; c. if the scalp is identified as having a dandruff condition or as being likely to develop a dandruff condition in step b), treating said scalp with a cosmetic treatment for the dandruff condition.
[0050] The amount of the active form of TGM3 is preferably measured as described in the “Prognostic and / or diagnostic method” section above.
[0051] The scalp sample of said subject and the subject may be as described in the "Prognostic and / or diagnostic method" section above.
[0052] By "cosmetic treatment against dandruff" is meant here any type of cosmetic treatment (topical or oral for example) intended to prevent, reduce or eliminate dandruff.
[0053] Said cosmetic treatment can be applied by any suitable route of administration, in particular topically or orally.
[0054] Said cosmetic treatment may be a cosmetic composition allowing the prevention, reduction and / or elimination of the dandruff condition, preferably for topical application. It may be presented for example in the form of shampoo or conditioner.
[0055] Cosmetic compositions allowing the prevention and / or reduction and / or elimination of the dandruff condition may comprise at least one anti-dandruff active agent chosen from ellagic acid, zinc pyrithione, piroctone olamine, selenium disulfide, and mixtures thereof.
[0056] In a particular embodiment, the scalp of said subject is diagnosed as being dandruff-prone or as being likely to develop a dandruff condition in step b) when the amount of the active form of TGM3 measured in step (a) in the scalp sample of the subject is greater, in particular significantly greater, than a control, as defined above.
[0057] Method for identifying a compound allowing the reduction and / or elimination of dandruff on a scalp
[0058] The present invention also relates to a method for identifying a compound allowing the prevention and / or reduction and / or elimination of the dandruff condition of a scalp, said method comprising the following steps:
[0059] a. measuring the amount of the active form of TGM3, in a sample of scalp exposed to said compound; b. comparing said quantity measured in step a) to the quantity of the active form of TGM3 in a sample of scalp not exposed to said compound; c. identify said compound as a compound for preventing and / or reducing and / or eliminating the dandruff condition of a scalp when a decrease in the amount of the active form of TGM3 in the scalp sample that has been exposed to said candidate compound is detected, compared to the amount of the active form of TGM3 in the scalp sample that has not been exposed to the candidate compound.
[0060] In a particular embodiment, the compound is identified as a compound allowing the prevention and / or reduction and / or elimination of the dandruff condition of a scalp when a significant decrease in the quantity of the active form of TGM3 in the scalp sample which has been exposed to said candidate compound is detected, compared to the quantity of the active form of TGM3 in the scalp sample which has not been exposed to the candidate compound.
[0061] The identification method of the invention is preferably carried out ex vivo.
[0062] According to one embodiment, the scalp sample used in the method identification according to the invention, is a sample taken, invasively or non-invasively, from the scalp of a subject presenting a dandruff condition.
[0063] According to one embodiment, the scalp sample used in the identification method according to the invention consists of a culture of cells derived from skin having hair or from a scalp, cells derived from skin having hair or from a scalp, a complete reconstructed scalp or an explant of human scalp.
[0064] According to one embodiment, the scalp sample used in the identification method according to the invention is a scalp sample obtained by rubbing the surface of the scalp, for example with a sterile cotton swab or swab, or by using an adhesive surface, for example a D-squame® disc.
[0065] Preferably, the scalp sample comes from the stratum corneum, in particular from the surface of the stratum corneum.
[0066] The amount of the active form of TGM3 is preferably measured as described in the “Prognostic and / or diagnostic method” section above.
[0067] By "significant decrease" within the meaning of the invention, we mean a statistically significant decrease in the quantity of the active form of TGM3.
[0068] In a variant, the invention relates to a method for evaluating the effectiveness of a cosmetic treatment against dandruff in a subject, said method comprising, after a step of applying said cosmetic treatment, a step (a) of measuring the quantity of the active form of transglutaminase 3 (TGM3), in a sample of scalp of said subject.
[0069] Preferably, this evaluation method further comprises the steps of:
[0070] b. comparing said quantity measured in step a) with a control;
[0071] c. determining whether said cosmetic treatment against dandruff is effective in said subject.
[0072] The method for evaluating the efficacy is preferably carried out in vitro or ex vivo.
[0073] The subject is preferably a human being having dandruff on the scalp. The subject is preferably between 20 and 70 years old.
[0074] The scalp sample of said subject may be as described in the section "Prognostic and / or diagnostic method" above.
[0075] The amount of the active form of transglutaminase is preferably measured as described in the section "Prognostic and / or diagnostic method" above.
[0076] In a particular embodiment, the control is the amount of the active form of transglutaminase 3 (TGM3) in a scalp sample of said subject before the application of said cosmetic treatment.
[0077] Preferably, said cosmetic treatment against dandruff is evaluated as being effective in said subject if the quantity of the active form of transglutaminase 3 measured in step (a) in the scalp sample of the subject is lower, in particular significantly lower than the control.
[0078] By "significantly lower" for the purposes of the invention, we mean a statistically significant decrease in the quantity of the active form of TGM3.
[0079] Kit
[0080] The invention relates to a kit comprising:
[0081] a. a means for measuring in a scalp sample, the quantity of the active form of TGM3, and b. an instruction leaflet.
[0082] By "means for measuring in a scalp sample, the quantity of the active form of TGM3" is meant a means for detecting or quantifying the active form of TGM3. In a particular embodiment of the invention, this means comprises a ligand specific for the active form of TGM3. In a particular embodiment of the invention, this means comprises a pair of capture and detection antibodies specific for the active form of TGM3.
[0083] In a particular embodiment of the invention, this means is a microfluidic cartridge comprising at least one antibody specific for the active form of TGM3. In another embodiment of the invention, this means is an immunochromatographic test comprising at least one antibody specific for the active form of TGM3.
[0084] According to one embodiment, the kit according to the invention further comprises a standard range of the active form of TGM3.
[0085] In a particular embodiment, the kit further comprises at least one means for taking a sample from the scalp. For example, the kit further comprises a sterile swab, or a cotton bud, or an adhesive surface, for example a D-squame® disc.
[0086] The invention also relates to the use of a kit according to the invention for the identification of a compound allowing the prevention and / or reduction and / or elimination of the dandruff condition of a scalp.
[0087] The present invention will be described in more detail by the figures and examples below. Brief description of the drawings
[0088] [Fig-1] [Fig.l] presents the linear regression based on the logarithm of the measurements TGM3 means versus overall dandruff status score. The logarithm average TGM3 measurements are on the ordinate and the film score is on the abscissa.
[0089] [Fig.2] [Fig.2] shows the ROC curve of using the logarithm of the amount of TGM3 to detect dandruff conditions of the scalp. Examples:
[0090] Example 1: Development of recombinant human antibodies directed against TGM3 and selection of an antibody pair
[0091] Highly specific recombinant human antibodies against TGM3 were generated using Bio-Rad AbD Serotec's HuCAL® technology. Briefly, a HuCAL® library containing 4.5 x 1010 antibodies, which are displayed on phage particles, was screened with 200 pg of the active form of human recombinant TGM3 protein. Three rounds of amplification were performed in E. coli using helper phage to enrich the selected antibody phage. DNA from the selected antibody phages was pooled and subcloned into a Fab expression vector - Fab-A_FSx2 format - bivalent Fab fusion antibody - bacterial alkaline phosphatase, followed by FLAG® and a His6 tag. After transformation and expression in E. coli, DNA from positive clones was selected and sequenced to identify unique antibody clones. Each unique clone was expressed in E. coli and purified by affinity chromatography.The affinity and specificity of each antibody were assessed by direct ELISA, using recombinant TGM3 and using unrelated antigens and markers.
[0092] Example 2: Sandwich test based on the TGM3 antibody Microfluidic cartridges
[0093] Customized TGM3 microfluidic cartridges were used to measure the amount of TGM3 in soluble protein extracts from stratum corneum samples collected using sterile swabs from the scalp of individuals with and without dandruff. Recombinant capture antibody was fixed inside the microfluidic grooves (NanoEnTek as described in published patent FR3023486). A standard curve, from 1 to 170 ng / ml was established using recombinant TGM3 (active form). Proteins from the sample on the sterile swab were solubilized in a buffer (50 mM Tris, 150 mM NaCl, pH 8.0) and 35 μl was injected inside the microfluidic cartridges. Detection was performed using fluorescent beads coated with an anti-TGM3 detection antibody. Example 3: Clinical Study Study Design
[0094] This is a single-center, double-blind, randomized, comparative study with 3 Parallel groups under medical supervision. A 2-week treatment-free period is followed by 4 weeks of treatment. Treatments consist of the use of a shampoo. Three shampoos are tested and each condition is monitored on a sample of 20 people.
[0095] The individuals selected for the study are healthy male or female volunteers, aged 18 to 60 years inclusive, with hair length greater than 2 cm and preferably shorter than shoulder length; with moderate to severe dandruff of the scalp; usually using shampoo 3 times / week and wishing to have three shampoos per week during the study; Evaluation criteria
[0096] The main criterion is the overall score of the dandruff condition of the scalp: evaluation of adherent and non-adherent dandruff according to an ordinal scale ranging from 0 to 5 (total dandruff score ranging from 0 to 10), at baseline and after 4 weeks of treatment. Analysis of results
[0097] TGM3 protein concentration was transformed to logarithmic scale.
[0098] Volunteers were classified as dandruff '+' or based on their overall dandruff condition score (adherent + non-adherent dandruff) of the entire scalp area following these rules:
[0099] Dandruff '+' = (overall dandruff condition score) > 2.5
[0100] Dandruff = (overall dandruff condition score) <1
[0101] Linear regression
[0102] [Fig.l] represents the linear regression based on the mean TGM3 measurements against the overall dandruff condition score.
[0103] The analysis suggests a good correlation between TGM3 concentration and the overall film condition score with a coefficient of determination R2 of 0.968.
[0104] ROC curve
[0105] The receiver operating characteristic function, or ROC curve, is a graphical plot that illustrates the diagnostic ability of a binary classification system as its discrimination threshold varies. The true positive rate is also known as sensitivity. The false positive rate is also called the false alarm probability and can be calculated as (1 - specificity).
[0106] [Fig.2] represents the ROC curve of using the logarithm of the amount of TGM3 to detect film conditions.
[0107] This analysis makes it possible to determine the threshold which most differentiates the two groups (with and without dandruff) and the sensitivity and specificity of the biomarker.
[0108] Based on the best sensitivity and specificity of the ROC curve, the threshold for separating the two groups is here 10.44 ng / ml of TGM3 (or 2.346 on a logarithmic scale, corresponding to the third point from the left in [Fig.2]).
Claims
Claims
1. Method for prognosis and / or diagnosis of a dandruff condition of the scalp, in a subject, said method comprising the following step: a. measure the amount of the active form of transglutaminase 3 (TGM3) in a scalp sample of said subject.
2. Method for preventing and / or cosmetically treating the scalp with a dandruff condition in a subject, said method comprising the following steps: a. measuring the quantity of the active form of TGM3, in a sample of scalp of said subject; b. deducing from step a) whether the scalp of said subject has a dandruff condition or whether the scalp of said subject is likely to develop a dandruff condition; c. if the scalp is identified as having a dandruff condition or as being likely to develop a dandruff condition in step b), treating said scalp with a cosmetic composition against the dandruff condition.
3. A method of identifying a compound for preventing and / or reducing and / or eliminating dandruff on the scalp, said method comprising the following steps: a. measuring the amount of the active form of TGM3 in a scalp sample exposed to said candidate compound; b. comparing said quantity measured in step a) to the quantity of the active form of TGM3 in a sample of scalp not exposed to said compound; c. identifying said candidate compound as a compound for preventing and / or reducing and / or eliminating the dandruff condition of a scalp when a decrease in the amount of the active form of TGM3 in the scalp sample that has been exposed to said candidate compound is detected, compared to the amount of the active form of TGM3 in the scalp sample that has not been exposed to the candidate compound.
4. The method of claim 3, wherein said scalp sample consists of a culture of cells derived from hairy skin or scalp, cells derived from hairy skin or scalp, a reconstructed complete scalp, or a human scalp explant.
5. A method according to any one of claims 1 to 4, wherein the scalp sample is taken by rubbing the scalp surface or using an adhesive surface.
6. Method according to one of claims 1 to 5, wherein the amount of the active form of TGM3 is measured using a ligand specific for the active form of TGM3.
7. A kit comprising: a. a means for measuring in a scalp sample the amount of the active form of TGM3, and b. an instruction leaflet.
8. A kit according to claim 7, wherein the means for measuring, in a scalp sample, the amount of the active form of TGM3, comprises a ligand specific for the active form of TGM3.
9. A kit according to any one of claims 7 to 8, wherein the means for measurement in a scalp sample comprises an immunochromatographic test.
10. Use of a kit according to one of claims 7 to 9 for the identification of a compound allowing the prevention and / or reduction and / or elimination of the dandruff condition of a scalp.
